Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients

Cancer Treatment Reviews

Volumn 59, Issue , 2017, Pages 93-101

  Janku, Filip ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Clinical trial; Inhibitors; Laboratory; Lessons; Phosphoinositide 3 kinase; Solid tumors

Indexed keywords

ALPELISIB; ANTINEOPLASTIC AGENT; APITOLISIB; AZD 8186; BIMIRALISIB; BIOLOGICAL MARKER; BUPARLISIB; COPANLISIB; DACTOLISIB; GEDATOLISIB; GSK 2636771; IPI 549; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OMIPALISIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTILISIB; PILARALISIB; SAR 260301; SERABELISIB; SONOLISIB; TASELISIB; UNCLASSIFIED DRUG; EVEROLIMUS; PROTEIN KINASE INHIBITOR; RAPAMYCIN; TEMSIROLIMUS;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; MONOTHERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SOLID MALIGNANT NEOPLASM; ANALOGS AND DERIVATIVES; ANIMAL; DRUG APPROVAL; DRUG EFFECTS; FEMALE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GENETICS; MALE; MOLECULARLY TARGETED THERAPY; MORTALITY; NEOPLASMS; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

ANIMALS; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG APPROVAL; EVEROLIMUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SIROLIMUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85026529710     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2017.07.005     Document Type: Review

References (105)

1. Vanhaesebroeck, B., Vogt, P.K., Rommel, C., PI3K: from the bench to the clinic and back. Curr Top Microbiol Immunol 347 (2010), 1–19.
2. Liu, P., Cheng, H., Roberts, T.M., Zhao, J.J., Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8 (2009), 627–644.
3. Engelman, J.A., Luo, J., Cantley, L.C., The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7 (2006), 606–619.
4. Markman, B., Tao, J.J., Scaltriti, M., PI3K pathway inhibitors: better not left alone. Curr Pharm Des 19 (2013), 895–906.
5. Dienstmann, R., Rodon, J., Serra, V., Tabernero, J., Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther 13 (2014), 1021–1031.
6. Jia, S., Roberts, T.M., Zhao, J.J., Should individual PI3 kinase isoforms be targeted in cancer?. Curr Opin Cell Biol 21 (2009), 199–208.
7. Arcaro, A., Wymann, M.P., Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem J 296:Pt 2 (1993), 297–301.
8. Vlahos, C.J., Matter, W.F., Hui, K.Y., Brown, R.F., A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269 (1994), 5241–5248.
9. Akinleye, A., Avvaru, P., Furqan, M., Song, Y., Liu, D., Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol, 6, 2013, 88.
10. Afinitor (everolimus) [package insert]. Novartis Pharmaceuticals Corporation. East Hanover, NJ; 2016.
11. Torisel (temsirolimus) [package insert]. Philadelphia, PA 19101: Wyeth Pharmaceuticals Inc., Pfizer Inc.; 2016.
12. Kwitkowski, V.E., Prowell, T.M., Ibrahim, A., Farrell, A.T., Justice, R., Mitchell, S.S., et al. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 15 (2010), 428–435.
13. Baselga, J., Campone, M., Piccart, M., Burris, H.A. 3rd, Rugo, H.S., Sahmoud, T., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366 (2012), 520–529.
14. Janku, F., Bringing target-matched PI3King from the bench to the clinic. Cell Cycle 12 (2013), 1817–1818.
15. Dogruluk, T., Tsang, Y.H., Espitia, M., Chen, F., Chen, T., Chong, Z., et al. Identification of variant-specific functions of PIK3CA by rapid phenotyping of rare mutations. Cancer Res 75 (2015), 5341–5354.
16. Janku, F., Hong, D.S., Fu, S., Piha-Paul, S.A., Naing, A., Falchook, G.S., et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep 6 (2014), 377–387.
17. O'Brien, N., Tong, L., Ayala, R., Issakhanian, S., McDonald, K., Hurvitz, S., et al. Targeting PI3K overcomes in vivo resistance to everolimus in estrogen receptor (ER+) breast cancer. Cancer Res, 73(suppl; abstr PD1-5), 2013.
18. Maira, S.M., Pecchi, S., Huang, A., Burger, M., Knapp, M., Sterker, D., et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-Kinase inhibitor. Mol Cancer Ther 11 (2012), 317–328.
19. Rodon, J., Brana, I., Siu, L.L., De Jonge, M.J., Homji, N., Mills, D., et al. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs 32 (2014), 670–681.
20. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer. Version 2; 2016.
21. Ciruelos Gil, E.M., Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat Rev 40 (2014), 862–871.
22. Ma, C.X., Luo, J., Naughton, M., Ademuyiwa, F., Suresh, R., Griffith, M., et al. A phase I trial of BKM120 (buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor-positive metastatic breast cancer. Clin Cancer Res 22 (2016), 1583–1591.
23. Baselga, J., Im, S.A., Iwata, H., Cortes, J., De Laurentiis, M., Jiang, Z., et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18 (2017), 904–916.
24. Di Leo, A., Keun, S., Ciruelos, E., Lønning, P., Janni, W., O'Regan, R., et al. BELLE-3: a phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2-, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment. Cancer Res, 77(suppl; abstr S4-07), 2017.
25. Mayer, I.A., Abramson, V.G., Isakoff, S.J., Forero, A., Balko, J.M., Kuba, M.G., et al. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 32 (2014), 1202–1209.
26. Shah, S., Chen, B., Testing for HER2 in breast cancer: a continuing evolution. Patholog Res Int, 2011, 2010, 903202.
27. Maira, S.M., Pecchi, S., Huang, A., Burger, M., Knapp, M., Sterker, D., et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 11 (2012), 317–328.
28. Saura, C., Bendell, J., Jerusalem, G., Su, S., Ru, Q., Buck, S., et al. Phase Ib study of buparlisib plus trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on trastuzumab-based therapy. Clin Cancer Res 20 (2014), 1935–1945.
29. Nanni, P., Nicoletti, G., Palladini, A., Croci, S., Murgo, A., Ianzano, M.L., et al. Multiorgan metastasis of human HER-2 + breast cancer in Rag2−/−;Il2rg−/− mice and treatment with PI3K inhibitor. PLoS ONE, 7, 2012, e39626.
30. Maira, M., Schnell, C., Lollini, P., Chouaid, C., Schmid, P., Nanni, P., et al. Preclinical and preliminary clinical activity of NVP-BKM120, an oral pan-class I PI3K inhibitor, in the brain. Ann Oncol, 23(suppl; abstr 1675P), 2012.
31. Engelman, J.A., Chen, L., Tan, X., Crosby, K., Guimaraes, A.R., Upadhyay, R., et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14 (2008), 1351–1356.
32. Zito, C.R., Jilaveanu, L.B., Anagnostou, V., Rimm, D., Bepler, G., Maira, S.M., et al. Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells. PLoS ONE, 7, 2012, e31331.
33. Jin, G., Kim, M.J., Jeon, H.S., Choi, J.E., Kim, D.S., Lee, E.B., et al. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer 69 (2010), 279–283.
34. Vansteenkiste, J.F., Canon, J.L., Braud, F.D., Grossi, F., De Pas, T., Gray, J.E., et al. Safety and efficacy of buparlisib (BKM120) in patients with PI3K pathway-activated non-small cell lung cancer: Results from the phase II BASALT-1 study. J Thorac Oncol 10 (2015), 1319–1327.
35. Sacco, A.G., Cohen, E.E., Current treatment options for recurrent or metastatic head and neck squamous cell carcinoma. J Clin Oncol 33 (2015), 3305–3313.
36. Fokas, E., Im, J.H., Hill, S., Yameen, S., Stratford, M., Beech, J., et al. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res 72 (2012), 239–248.
37. Soulieres, D., Faivre, S., Mesia, R., Remenar, E., Li, S.H., Karpenko, A., et al. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol 18 (2017), 323–335.
38. Brisson, R., Dekker, A., De Souza, J., Saloura, V., Vokes, E., Seiwert, T., A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent/metastatic head and neck cancer. J Clin Oncol, 35(suppl; abstr 6039), 2017.
39. Britten, C.D., PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. Cancer Chemother Pharmacol 71 (2013), 1395–1409.
40. Vakiani, E., Solit, D.B., KRAS and BRAF: drug targets and predictive biomarkers. J Pathol 223 (2011), 219–229.
41. Janku, F., Wheler, J.J., Naing, A., Falchook, G.S., Hong, D.S., Stepanek, V.M., et al. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res 73 (2013), 276–284.
42. Janku, F., Wheler, J.J., Westin, S.N., Moulder, S.L., Naing, A., Tsimberidou, A.M., et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 30 (2012), 777–782.
43. Bedard, P.L., Tabernero, J., Janku, F., Wainberg, Z.A., Paz-Ares, L., Vansteenkiste, J., et al. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin Cancer Res 21 (2015), 730–738.
44. Folkes, A.J., Ahmadi, K., Alderton, W.K., Alix, S., Baker, S.J., Box, G., et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin -4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 51 (2008), 5522–5532.
45. Sarker, D., Ang, J.E., Baird, R., Kristeleit, R., Shah, K., Moreno, V., et al. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res 21 (2015), 77–86.
46. Krop, I.E., Mayer, I.A., Ganju, V., Dickler, M., Johnston, S., Morales, S., et al. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 17 (2016), 811–821.
47. Vuylsteke, P., Huizing, M., Petrakova, K., Roylance, R., Laing, R., Chan, S., et al. Pictilisib plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study. Ann Oncol 27 (2016), 2059–2066.
48. Hong, D.S., Bowles, D.W., Falchook, G.S., Messersmith, W.A., George, G.C., O'Bryant, C.L., et al. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 18 (2012), 4173–4182.
49. Bowles, D.W., Ma, W.W., Senzer, N., Brahmer, J.R., Adjei, A.A., Davies, M., et al. A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. Br J Cancer 109 (2013), 1085–1092.
50. Jimeno, A., Bauman, J.E., Weissman, C., Adkins, D., Schnadig, I., Beauregard, P., et al. A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. Oral Oncol 51 (2015), 383–388.
51. Levy, B., Spira, A., Becker, D., Evans, T., Schnadig, I., Camidge, D.R., et al. A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer. J Thorac Oncol 9 (2014), 1031–1035.
52. Parsons, D.W., Jones, S., Zhang, X., Lin, J.C., Leary, R.J., Angenendt, P., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321 (2008), 1807–1812.
53. Weber, G.L., Parat, M.O., Binder, Z.A., Gallia, G.L., Riggins, G.J., Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. Oncotarget 2 (2011), 833–849.
54. Pitz, M.W., Eisenhauer, E.A., MacNeil, M.V., Thiessen, B., Easaw, J.C., Macdonald, D.R., et al. Phase II study of PX-866 in recurrent glioblastoma. Neuro Oncol 17 (2015), 1270–1274.
55. Shapiro, G.I., Rodon, J., Bedell, C., Kwak, E.L., Baselga, J., Brana, I., et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin Cancer Res 20 (2014), 233–245.
56. Tolaney, S., Burris, H., Gartner, E., Mayer, I.A., Saura, C., Maurer, M., et al. Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer. Breast Cancer Res Treat 149 (2015), 151–161.
57. Slomovitz, B.M., Coleman, R.L., The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res 18 (2012), 5856–5864.
58. Matulonis, U., Vergote, I., Backes, F., Martin, L.P., McMeekin, S., Birrer, M., et al. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol 136 (2015), 246–253.
59. Liu, N., Rowley, B.R., Bull, C.O., Schneider, C., Haegebarth, A., Schatz, C.A., et al. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110alpha and p110delta activities in tumor cell lines and xenograft models. Mol Cancer Ther 12 (2013), 2319–2330.
60. Patnaik, A., Appleman, L.J., Tolcher, A.W., Papadopoulos, K.P., Beeram, M., Rasco, D.W., et al. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas. Ann Oncol 27 (2016), 1928–1940.
61. Maira, S.M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7 (2008), 1851–1863.
62. Schnell, C.R., Stauffer, F., Allegrini, P.R., O'Reilly, T., McSheehy, P.M., Dartois, C., et al. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res 68 (2008), 6598–6607.
63. Serra, V., Markman, B., Scaltriti, M., Eichhorn, P.J., Valero, V., Guzman, M., et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68 (2008), 8022–8030.
64. Brachmann, S., Fritsch, C., Maira, S.M., Garcia-Echeverria, C., PI3K and mTOR inhibitors: a new generation of targeted anticancer agents. Curr Opin Cell Biol 21 (2009), 194–198.
65. Yasumizu, Y., Miyajima, A., Kosaka, T., Miyazaki, Y., Kikuchi, E., Oya, M., Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer. J Urol 191 (2014), 227–234.
66. Nyfeler, B., Chen, Y., Li, X., Pinzon-Ortiz, M., Wang, Z., Reddy, A., et al. RAD001 enhances the potency of BEZ235 to inhibit mTOR signaling and tumor growth. PLoS ONE, 7, 2012, e48548.
67. O'Brien, N.A., McDonald, K., Tong, L., von Euw, E., Kalous, O., Conklin, D., et al. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT. Clin Cancer Res 20 (2014), 3507–3520.
68. Bendell, J.C., Kurkjian, C., Infante, J.R., Bauer, T.M., Burris, H.A. 3rd, Greco, F.A., et al. A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors. Invest New Drugs 33 (2015), 463–471.
69. Liu, T., Sun, Q., Li, Q., Yang, H., Zhang, Y., Wang, R., et al. Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma. Mol Cancer Ther 14 (2015), 429–439.
70. Park, H., Kim, Y., Sul, J.W., Jeong, I.G., Yi, H.J., Ahn, J.B., et al. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer. Prostate 75 (2015), 1747–1759.
71. Munster, P., Aggarwal, R., Hong, D., Schellens, J.H., van der Noll, R., Specht, J., et al. First-in-human phase I study of GSK2126458, an oral pan-class I phosphatidylinositol-3-kinase inhibitor, in patients with advanced solid tumor malignancies. Clin Cancer Res 22 (2016), 1932–1939.
72. Grilley-Olson, J.E., Bedard, P.L., Fasolo, A., Cornfeld, M., Cartee, L., Razak, A.R., et al. A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors. Invest New Drugs 34 (2016), 740–749.
73. Mallon, R., Feldberg, L.R., Lucas, J., Chaudhary, I., Dehnhardt, C., Santos, E.D., et al. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. Clin Cancer Res 17 (2011), 3193–3203.
74. Shapiro, G.I., Bell-McGuinn, K.M., Molina, J.R., Bendell, J., Spicer, J., Kwak, E.L., et al. First-in-human study of PF-05212384 (PKI-587), a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer. Clin Cancer Res 21 (2015), 1888–1895.
75. Wallin, J.J., Edgar, K.A., Guan, J., Berry, M., Prior, W.W., Lee, L., et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther 10 (2011), 2426–2436.
76. Dolly, S.O., Wagner, A.J., Bendell, J.C., Kindler, H.L., Krug, L.M., Seiwert, T.Y., et al. Phase I study of apitolisib (GDC-0980), dual phosphatidylinositol-3-kinase and mammalian target of rapamycin kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 22 (2016), 2874–2884.
77. Adjei, A.A., Dy, G.K., Zhao, Y., Ma, W.W., Opyrchal, M., Bakhribah, H., et al. A phase 1 study of the PI3K/mTOR inhibitor PQR309 evaluating safety, pharmacokinetics (PK) and pharmacodynamics (PD) in patients (pts) with advanced solid tumors. J Clin Oncol, 34(suppl; abstr 2560), 2016.
78. Fritsch, C., Huang, A., Chatenay-Rivauday, C., Schnell, C., Reddy, A., Liu, M., et al. Characterization of the novel and specific PI3Kalpha inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther 13 (2014), 1117–1129.
79. Juric, D., Burris, H., Schuler, M., Schellens, J., Berlin, J., Seggewiss-Bernhardt, R., et al. Phase I study of the PI3K-alpha inhibitor BYL719, as a single agent in patients with advanced solid tumors (sAT). Ann Oncol, 25(suppl; abstr 451PD), 2014.
80. Juric D, André F, Rugo H, Mayer I, Loibl S, Sheng Q, et al. Combined alpelisib (BYL719) and fulvestrant in PIK3CA mutant or wild-type estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. In: 33rd Annual Miami Breast Cancer Conference 2016, Abstract 334.
81. Sheng, Q., Wang, H.Q., Das, R., Chen, Y., Liang, J., Cao, A., et al. Targeting HER3 and PI3k in head and neck squamous cancer cells. Cancer Res, 73(suppl; abstr 4261), 2013.
82. Munster, P., Elkabets, M., Gilbert, J., Razak, A.R.A., Ahn, M., Yen, C., et al. Inhibition of PIK3CA with BYL719 can overcome resistance to cetuximab in squamous cell carcinoma of the head and neck (SCCHN). Mol Cancer Ther, 14(suppl; abstr A46), 2015.
83. Razak, A.R.A., Ahn, M., Yen, C., Solomon, B.J., Lee, S., Wang, H., et al. Phase lb/ll study of the PI3Kα inhibitor BYL719 in combination with cetuximab in recurrent/metastatic squamous cell cancer of the head and neck (SCCHN). J Clin Oncol, 32(suppl; abstr 6044), 2014.
84. van Geel, R.M.J.M., Tabernero, J., Elez, E., Bendell, J.C., Spreafico, A., Schuler, M., et al. A phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer. Cancer Discov 7 (2017), 610–619.
85. Juric, D., Krop, I., Ramanathan, R., Xiao, J., Sanabria, S., Wilson, T., et al. GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study. Cancer Res, 73(suppl; abstr LB-64), 2013.
86. Song, K., Edgar, K., Kirkpatrick, D., Phu, L., Schmidt, S., Nannini, M., et al. The PI3K inhibitor, taselisib, has a unique mechanism of action that leads to enhanced potency in PIK3CA mutant models. Cancer Res, 77(suppl; abstr S6-04), 2017.
87. Olivero, G., Heffron, T., Baumgardner, M., Belvin, M., Ross, L., Blaquiere, N., et al. Discovery of GDC-0032: a beta-sparing PI3K inhibitor active against PIK3CA mutant tumors. Cancer Res, 73(suppl; abstr DDT02-01), 2013.
88. Juric, D., Krop, I., Ramanathan, R.K., Wilson, T.R., Ware, J.A., Sanabria Bohorquez, S.M., et al. Phase I dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumors. Cancer Discov 7 (2017), 704–715.
89. Juric, D., De Bono, J.S., LoRusso, P.M., Nemunaitis, J., Heath, E.I., Kwak, J.L., et al. A first-in-human, phase I, dose-escalation study of TAK-117, a selective PI3Kalpha; isoform inhibitor, in patients with advanced solid malignancies. Clin Cancer Res, 2017, 10.1158/1078-0432.CCR-16-2888.
90. Juric, D., De Bono, S., LoRusso, P., Zohren, F., Shou, Y., Tabernero, J., First-in-human, phase I, dose-escalation study of selective PI3Kα isoform inhibitor MLN1117 in patients (pts) with advanced solid malignancies. J Clin Oncol, 33(suppl; abstr 512), 2015.
91. Ni, J., Liu, Q., Xie, S., Carlson, C., Von, T., Vogel, K., et al. Functional characterization of an isoform-selective inhibitor of PI3K-p110beta as a potential anticancer agent. Cancer Discov 2 (2012), 425–433.
92. Berenjeno, I.M., Guillermet-Guibert, J., Pearce, W., Gray, A., Fleming, S., Vanhaesebroeck, B., Both p110alpha and p110beta isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor. Biochem J 442 (2012), 151–159.
93. Weigelt, B., Warne, P.H., Lambros, M.B., Reis-Filho, J.S., Downward, J., PI3K pathway dependencies in endometrioid endometrial cancer cell lines. Clin Cancer Res 19 (2013), 3533–3544.
94. Schmit, F., Utermark, T., Zhang, S., Wang, Q., Von, T., Roberts, T.M., et al. PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. Proc Natl Acad Sci U S A 111 (2014), 6395–6400.
95. Virone-Oddos, A., Bonnevaux, H., Lemaitre, O., Vincent, L., Halley, F., Demers, B., et al. Discovery and characterization of SAR260301, a novel PI3Kβ-selective inhibitor in clinical development for the treatment of PTEN-deficient tumors. Cancer Res, 73(suppl; abstr 3258), 2013.
96. Arkenau, H., Mateo, J., Lemech, C.R., Infante, J.R., Burris, H.A., Bang, Y., et al. A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors. J Clin Oncol, 32(suppl; abstr 2514), 2014.
97. Hancox, U., Cosulich, S., Hanson, L., Trigwell, C., Lenaghan, C., Ellston, R., et al. Inhibition of PI3Kbeta signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel. Mol Cancer Ther 14 (2015), 48–58.
98. Bedard, P., Davies, M., Kopetz, S., Flaherty, K., Shapiro, G., John Luke, J., et al. First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737). J Clin Oncol, 33(suppl; abstr 2564), 2015.
99. Hirsch, E., Lembo, G., Montrucchio, G., Rommel, C., Costa, C., Barberis, L., Signaling through PI3Kgamma: a common platform for leukocyte, platelet and cardiovascular stress sensing. Thromb Haemost 95 (2006), 29–35.
100. De Henau, O., Merghoub, T., Winkler, D., Sharma, S., Pink, M., Tchaicha, J., et al. Checkpoint blockade therapy is improved by altering the immune suppressive microenvironment with IPI-549, a potent and selective inhibitor of PI3K-gamma, in preclinical models. Cancer Res, 76(suppl; abstr 554), 2016.
101. Tolcher, A., Hong, D., Sullivan, R., Mier, J., Shapiro, G., Pearlberg, J., et al. IPI-549-01-A phase 1/1b first in human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with pembrolizumab in subjects with advanced solid tumors. J Clin Oncol, 34(suppl; abstr TPS3111), 2016.
102. Janku, F., Tsimberidou, A.M., Garrido-Laguna, I., Wang, X., Luthra, R., Hong, D.S., et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 10 (2011), 558–565.
103. Juric, D., Castel, P., Griffith, M., Griffith, O.L., Won, H.H., Ellis, H., et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kalpha inhibitor. Nature 518 (2015), 240–244.
104. Janku, F., Hong, D.S., Fu, S., Piha-Paul, S.A., Naing, A., Falchook, G.S., et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep 6 (2014), 377–387.
105. Polivka, J. Jr, Janku, F., Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther 142 (2014), 164–175.